The DLBCL90 gene‐expression assay identifies double‐hit lymphomas with high sensitivity in patients from two phase II clinical trials with high‐risk diffuse large B‐cell lymphoma

ABSTRACT:

SUBMITTER: Isaksen K 

PROVIDER: S-EPMC9175840 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature